OMICS International Organises 3000+ Global Conferenceseries Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
For more Conferences visit


Manya Aggarwal

Manya Aggarwal

Decision Resources Group, Canada

Title: Innovations in diabetes care devices and their life changing implications


Manya Aggarwal is a Senior Analyst at Decision Resources Group. She has authored several reports on the Diabetes, Laparoscopic and Gynecological device markets in the Endoscopy division of the company. Prior to joining Decision Resources Group, Manya worked as an Economist at a healthcare startup based out of Toronto. Manya holds a Master Degree in Financial Economics and a Bachelor’s degree in Commerce and Economics from the University of Toronto.


According to the World Health Organization, over 6% of the world’s population lived with diabetes in 2014. This number is expected to increase to almost 8% by 2030. This makes the diabetes market one of the fastest-growing and most lucrative markets in the whole world. Medical device companies are therefore investing tremendous amounts of resources in new innovations that can make this chronic disease easier to manage. In my session, I would like to talk about the current market for diabetes devices (consisting of insulin pens, syringes, vials, self-monitoring blood glucose and continuous glucose monitoring devices) as well as address the following innovations and their impact on people living with diabetes: 1) Medtronic’s MiniMed 640Gdevice, which is currently still awaiting approval in the US, is a definite step in the direction of the creation of an “artificial pancreas”. I want to discuss how this novel device will make diabetes management more automated for type 1 diabetics. 2) Intarcia Therapeutics’ implantable pump device called the ITCA 650, is a thin implantable pump that holds the drug exenatide. Once commercially available, the pump would be implanted in abdominal tissue releasing the drug slowly over a period of approximately a year. I want to discuss how this would make diabetes management more automated for type 2 diabetics 3) CGM device innovations like the Senseonics CGM System and the GlySens ICGM which will both make continuous glucose monitoring much easier for type 1 diabetics